Join our clinical trials with GMP-grade stem cells.
Access advanced stem cell treatment through our patient-funded research programs, featuring rigorously tested bone marrow-derived Mesenchymal Stem Cells, the same GMP-certified cells used by top medical institutions worldwide. Every step is guided by expert medical care, uncompromising safety protocols, and personalized support throughout your journey.
We conduct specialized clinical trials with cutting-edge stem cell treatments in three critical areas where stem cell science shows great potential for your health: protecting your heart, restoring your joints and muscles, and supporting your healthy aging journey.
This is done through our patient-funded research programs. Join our trials and get access to all the benefits of being part of groundbreaking medical research:
Each study follows strict scientific processes designed to advance regenerative medicine while providing you with access to stem cell treatment of unmatched quality.
Together, we’re revolutionising health – today and for generations to come.
Ready to explore if you qualify? Our medical team will guide you through the process to determine which program might be right for your unique health journey.
This clinical trial investigates the potential of MSCs in prevention of cardiovascular disease and follows several longevity and disease biomarkers. Cardiovascular disease is the leading cause of death globally, taking an estimated 20 million lives each year. Prevention is a proactive approach to healthcare that seeks to maintain health and prevent development of illness.
You may be eligible if you:
Musculoskeletal injuries and degeneration may occur for various reasons, such as accidents, sports injuries, genetics, or just wear and tear. Depending on your condition you may be eligible for local and/or systemic treatment.
You may be eligible if you are 18 years or older and have:
The geriatric syndrome of frailty is a common clinical syndrome based on the accumulation of multi-systemic function declines and the increase in susceptibility to stressors during biological ageing. This can manifest in a variety of symptoms, such as decreased muscle strength, reduced mobility, and impaired cognitive function. Frailty can also increase an elderly persons risk of falls, hospitalization, and other negative health outcomes.
You may be eligible if you:
Osteoarthritis (OA) is the most common form of arthritis and is also known as degenerative arthritis and OA. It occurs most frequently in the hands, hips, and knees. A common symptom of OA is a stiff and painful feeling around the joints.
Please note that this is not a separate trial. Treatments for OA will be included in the musculoskeletal injuries and degeneration trial.
About
Mesenchymal stem cells (MSCs) are a type of multipotent stem cell with anti-inflammatory, immunomodulatory and regenerative characteristics. They have been intensively researched over the past decades, and currently, there are hundreds of clinical trials with MSCs for a broad spectrum of conditions (1).
The MSCs used in these trials are produced by Cellcolabs AB at their facility in Stockholm, Sweden. The production process has been optimised through over 20 years of academic research, and the cells are quality controlled according to the guidelines of the International Society for Cell and Gene Therapy (2). The manufacturing is approved by the Swedish Medical Products Agency and certified under GMP (Good Manufacturing Practice) standards. The clinical trials have received approval by local authorities.
Cellcolabs’ MSCs are derived from the bone marrow of healthy donors aged 18-30. These cells are likely more potent than cells derived from trial participants themselves (3-4). Using donated cells also means that trial participants do not need to endure cell extraction as part of the trial.
The MSCs used in these trials are produced by Cellcolabs AB at their facility in Stockholm, Sweden. The production process has been optimised through 25 years of academic research, and the cells are quality controlled according to the guidelines of the International Society for Cell and Gene Therapy (2). The manufacturing is approved by the Swedish Medical Products Agency and certified under GMP (Good Manufacturing Practice) standards. The clinical trials have received approval by local authorities.
Cellcolabs’ MSCs are derived from the bone marrow of healthy donors aged 18-30. These cells are likely more potent than cells derived from trial participants themselves (3-4). Using donated cells also means that trial participants do not need to endure cell extraction as part of the trial.
Timeline
Clinics
Our clinical trials are conducted in the Bahamas, a country known for its high-quality healthcare and ambitious research in regenerative medicine.
The Bahamas is a destination for both tourism and medicine, and the country is at the forefront of clinical stem cell applications. They allow patient-funded clinical trials, which is an opportunity to accelerate the research.
Our local partnering physicians have long experience of stem cell therapies. The clinical trials are approved by the Bahamas National Stem Cell Ethics Committee.
2. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905
3. Schultz, M.B. and Sinclair, D.A., 2016. When stem cells grow old: phenotypes and mechanisms of stem cell aging. Development, 143(1), pp.3-14.
4. Karin Stenderup, Jeannette Justesen, Christian Clausen, Moustapha Kassem, Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells, Bone, Volume 33, Issue 6, 2003, Pages 919-926, ISSN 8756-3282, https://doi.org/10.1016/j.bone.2003.07.005.
